Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. - Wikidata - awgldk - TriplyDB

Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.

Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.

http://www.wikidata.org/entity/Q34105586

about

Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia Analyzing the roles of multi-functional proteins in cells: The case of arrestins and GRKs Targeting G protein coupled receptor-related pathways as emerging molecular therapies Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys Levodopa-induced dyskinesia is associated with increased thyrotropin releasing hormone in the dorsal striatum of hemi-parkinsonian rats Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.Adaptive gene regulation in the Striatum of RGS9-deficient mice PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking How genetic errors in GPCRs affect their function: Possible therapeutic strategies The role of GRK6 in animal models of Parkinson's disease and L-DOPA treatment GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.Double-dissociation of the catecholaminergic modulation of synaptic transmission in the oval bed nucleus of the stria terminalis.Current Experimental Studies of Gene Therapy in Parkinson's Disease Involvement of the bed nucleus of the stria terminalis in L-Dopa induced dyskinesia Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.Maladaptive striatal plasticity in L-DOPA-induced dyskinesia.Distinct cellular and subcellular distributions of G protein-coupled receptor kinase and arrestin isoforms in the striatum.In vivo optogenetic control of striatal and thalamic neurons in non-human primates Lentiviral-mediated gene transfer to the sheep brain: implications for gene therapy in Batten disease.Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia.L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission.4040 SNPs for genomic analysis in the rhesus macaque (Macaca mulatta)G Protein-coupled Receptor Kinases of the GRK4 Protein Subfamily Phosphorylate Inactive G Protein-coupled Receptors (GPCRs).G protein-coupled receptor kinases: more than just kinases and not only for GPCRs Modeling Parkinson's disease in primates: The MPTP model Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia Cognitive effects of dopamine depletion in the context of diminished acetylcholine signaling capacity in mice.NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.GRK6 regulates ROS response and maintains hematopoietic stem cell self-renewal Synthetic biology with surgical precision: targeted reengineering of signaling proteins.Beyond traditional pharmacology: new tools and approaches.G protein-coupled receptor kinases as regulators of dopamine receptor functions.Non-human primate models of PD to test novel therapies.Shp-2 knockdown prevents l-dopa-induced dyskinesia in a rat model of Parkinson's disease.Prognostic value of decreased GRK6 expression in lung adenocarcinoma.Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.Targeting individual GPCRs with redesigned nonvisual arrestins.

P2860

Q26773403-3F3E7015-CE1D-4F57-A028-F8ECD553D84F Q26785358-3DEC4993-1875-4933-83F1-2C1E2C5227E0 Q26829964-1CDC1A04-933F-48D4-BC23-08954FAB8AC8 Q27316473-C3D4EBDE-C2CF-435D-9A6E-FC95EE4AFDBA Q27316872-543E8FB8-17DA-408D-898C-682D020F57BA Q27324174-825DD6AE-BCE7-4DA7-BCBE-F9A9D807F65B Q28541409-61FF401E-6D93-49ED-8C4C-E68B067F3D7B Q28582674-6C0A4CAF-2729-450C-B54A-D65B8E57652A Q28646207-9332B32D-A62F-4F58-8EF8-1B6435E32112 Q30506209-FC8F7970-9C85-4879-B42E-9A6698B00300 Q30653115-815DFC2B-D117-4977-8A83-715BFB552845 Q30988635-F9FA3D23-FFF1-4603-BCF8-52983F969363 Q33573249-15F7B5FB-D623-43AE-A0B6-D44C59F0F070 Q33627771-7815056B-9D1C-4AC0-80A0-236ADED27A11 Q33725654-CAE7594D-2C98-4E26-BE80-FB546E1C22E7 Q33758221-2DE4AD59-21E8-4638-8AE2-5AE335401F23 Q34094008-6D6D86A9-8798-4637-96B2-9E2313631FCB Q34472138-3127ED42-60DF-4537-A2EE-73A08AE75F94 Q34505951-B4AE806C-AB76-4CBC-9EEA-6D2B508D81E1 Q35174910-FCF1C339-61C8-43E8-BBC5-A8E48EF2DFA9 Q35196371-FE3EA2E8-FEE8-4916-ABA3-F143F6DD0EF5 Q35324977-8AFBC34F-4ADE-4EEC-BBF0-2E75902B3F9D Q35424424-F7EF648E-EF05-46E0-B570-C422EF3B4574 Q35510971-34F00BBE-3997-4968-A006-28A5F13103C9 Q35536256-FC6306ED-CE65-4E94-A1B0-2B796795587D Q35621624-77E38044-630E-4148-8A72-46FC25812E97 Q35765748-CE42DCF3-E3CF-4478-877B-4F0C3C926568 Q35915318-1BC0588F-C422-4137-85D6-D69115B63A49 Q36486037-DDEC719C-4320-4CC7-8207-FEDAB2A4192C Q36738475-4502CE3E-30AA-43C4-A67C-479AC0EDE140 Q37486030-16E92964-1D81-450E-A856-880DF748E493 Q37603345-F3D241FB-F6C7-41BF-83FA-5C8700FA5620 Q38016028-AFED1B84-C825-4D41-B1DE-0C2815BC1B03 Q38311702-4DBB8246-7619-4348-9A37-FC1E9AA7AB43 Q38834292-529CC850-BD10-4FFE-AC4E-E164E591703E Q39229450-05793D3D-BC14-4D1E-B992-6E7064ADAADD Q39981493-F75963F2-F0B9-4804-9B9E-2646FEC75DF5 Q40492762-E7BED9EC-AB33-4855-9C6D-3EA1088BADB9 Q41584434-44580C1E-A1EC-4308-9242-B19F6C9A324C Q41872788-560E8143-F055-469A-B4DC-68D2D175A94A

P2860

Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.

http://www.wikidata.org/entity/Q34105586

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@ast

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@en

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@nl

type

label

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@ast

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@en

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@nl

prefLabel

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@ast

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@en

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@nl

P1433

Q34105586-6ADD174D-CE47-4454-8688-0AECF7C29D97

P1476

Q34105586-B6449605-8A3E-4164-9B39-48782118E97D

P2093

Q34105586-011A73F3-09D0-4399-9651-C15A175A30F3

Q34105586-199652A9-7420-429C-8081-D705C3A94703

Q34105586-3B5839D8-22F3-48F1-B141-D591929251C6

Q34105586-6012CEF3-4D5C-4ED9-B342-C1BBA6640BA4

Q34105586-7BAEB778-1BD9-426E-9E6E-DE1FFDE207FC

Q34105586-9152FC44-7F00-4901-828F-F5DB98FC156A

Q34105586-9C71997B-A2E3-466D-B17E-8C625AA50F6B

Q34105586-B0C557AF-9EBE-4814-AB47-AAADA70F41D0

Q34105586-B19FC666-A950-4B34-A63E-DDB9B131E37F

Q34105586-BC108A98-033E-4655-BB3C-92BDBD60860A

P2860

Q34105586-06AD74B8-6554-40F2-B855-881FA1BA8195

Q34105586-0C899013-70A7-4988-9AE2-9A5BCE86EDC3

Q34105586-0F3F5D6E-61A8-44FA-9B97-C8842912D8DB

Q34105586-10D7420A-562C-4DE7-BF5B-753B5740EDEA

Q34105586-12BC03A5-CD23-428C-BC71-BC21420AC799

Q34105586-17435302-E1E6-47CC-9725-76DF83AFC0F0

Q34105586-1A6C7D73-21EF-4C59-BAB4-1CC7EF9E6A2B

Q34105586-2AE46F39-5497-452D-A830-A5FF011F5D48

Q34105586-37A7082A-36D9-4EAA-AA1D-FD6FA059DDE3

Q34105586-3C01CC25-ECE0-45C4-A037-C0DEE54CCEFC

P304

Q34105586-3F973DA5-1E09-4730-9E40-7B8345B87435

P31

Q34105586-1FA39BC6-2DC0-4583-A618-DAEEAB8CA05E

P356

Q34105586-A6DD6CC7-ED7F-46A6-A4C7-BC978B999651

P407

Q34105586-FD23B413-A8BE-490A-A01D-85292960B47B

P433

Q34105586-D730E92B-7291-4EAE-AECE-01C5E600E595

P478

Q34105586-774BA7C1-C797-427C-A30F-FC954E69EC47

P577

Q34105586-4BA57131-0AED-4833-92C8-3EA0E6961E78

P5875

Q34105586-7D8DCAF5-B8BC-4037-8810-B239A4B3EDE1

P698

Q34105586-56D28B47-EE8C-4D04-8170-7A8515AC0A1F

P921

Q34105586-233861E6-D874-45ED-9E1A-E31505C0FCE4

Q34105586-5EFFF1EA-0210-440A-8379-E183C5F64E2C

Q34105586-7E26CE92-2907-4FEB-861D-7F95F5FEE8AC

P932

Q34105586-4C2DE384-BE8F-4952-915D-548CE4B3F899

P356

SCITRANSLMED.3000664

P1433

Science Translational Medicine

P1476

Lentiviral overexpression of G ...... erimental Parkinson's disease.

@en

P2093

Amandine Berthet

http://www.w3.org/2001/XMLSchema#string

Bernard H Bioulac

http://www.w3.org/2001/XMLSchema#string

Bertrand Bloch

http://www.w3.org/2001/XMLSchema#string

Erwan Bezard

http://www.w3.org/2001/XMLSchema#string

Eugenia V Gurevich

http://www.w3.org/2001/XMLSchema#string

Evelyne Doudnikoff

http://www.w3.org/2001/XMLSchema#string

Evgeny Bychkov

http://www.w3.org/2001/XMLSchema#string

Gregory Porras

http://www.w3.org/2001/XMLSchema#string

Incarnation Aubert

http://www.w3.org/2001/XMLSchema#string

Mohamed R Ahmed

http://www.w3.org/2001/XMLSchema#string

P2860

Arrestins: ubiquitous regulators of cellular signaling pathways

DARPP-32: regulator of the efficacy of dopaminergic neurotransmission

Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice

Regulation of receptor trafficking by GRKs and arrestins

Enhanced morphine analgesia in mice lacking beta-arrestin 2

The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain

Cellular regulation of RGS proteins: modulators and integrators of G protein signaling

Beta-arrestins and cell signaling

Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.

P304

28ra28

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3000664

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43247700

http://www.w3.org/2001/XMLSchema#string

P698

20410529

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2933751

http://www.w3.org/2001/XMLSchema#string